BiomX is a microbiome drug discovery company developing customized phage therapies that seek and destroy harmful bacteria in chronic diseases such as inflammatory bowel disease (IBD) and cancer. They discover and validate proprietary bacterial targets and customize their natural and engineered phage compositions against these targets. The Company’s platforms use computational and synthetic biology and cutting-edge research from Profs. Rotem Sorek, Ph.D., Eran Elinav, M.D., Ph.D., and Eran Segal, Ph.D., of The Weizmann Institute of Science; and Professor Timothy K. Lu, M.D., Ph.D., of The Massachusetts Institute of Technology. Investors in the Company include OrbiMed Israel Incubator LP, Johnson & Johnson Development Corporation Inc., Takeda Ventures, Inc., Seventure Partners, Mirae Asset, and SBI.
Their pipeline of customized phage cocktails comprises products in pre-clinical stages addressing acne, IBD, cancer and liver disease. BiomX plans to file an IND application with the US FDA for BX002 in 2019.